CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping influenza treatment industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in incidences of influenza across the globe
3.4.1.2. Increase in healthcare expenditure worldwide
3.4.1.3. Rise in R&D investments for discovery of new drugs
3.4.2. Restraint
3.4.2.1. Presence of substitutes for the treatment of influenza
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analysis

CHAPTER 4: INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Peramivir
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Zanamivir
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Oseltamivir Phosphate
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Baloxavir Marboxil
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Other products
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Retail Pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Hospital Pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: INFLUENZA TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by product type
6.2.2.1.2. U.S. market size and forecast, by distribution channel
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by product type
6.2.2.2.2. Canada market size and forecast, by distribution channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by product type
6.2.2.3.2. Mexico market size and forecast, by distribution channel
6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by product type
6.3.2.1.2. Germany market size and forecast, by distribution channel
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by product type
6.3.2.2.2. France market size and forecast, by distribution channel
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by product type
6.3.2.3.2. UK market size and forecast, by distribution channel
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by product type
6.3.2.4.2. Italy market size and forecast, by distribution channel
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by product type
6.3.2.5.2. Rest of Europe market size and forecast, by distribution channel
6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by product type
6.4.2.1.2. Japan market size and forecast, by distribution channel
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by product type
6.4.2.2.2. China market size and forecast, by distribution channel
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by product type
6.4.2.3.2. India market size and forecast, by distribution channel
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by product type
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel
6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by product type
6.5.2.1.2. Brazil market size and forecast, by distribution channel
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by product type
6.5.2.2.2. South Africa market size and forecast, by distribution channel
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by product type
6.5.2.3.2. Saudi Arabia market size and forecast, by distribution channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by product type
6.5.2.4.2. Rest of LAMEA market size and forecast, by distribution channel
6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by distribution channel

CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BioCryst Pharmaceuticals, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Daiichi Sankyo Company, Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. F. Hoffmann-La Roche AG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. GlaxoSmithKline Plc
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. MYLAN N.V
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. NATCO Pharma Limited
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. NOVARTIS AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. SANOFI
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

List of Tables

TABLE 01. GLOBAL INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE, 2018-2026 ($MILLION)
TABLE 02. PERAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 03. ZANAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 04. OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 05. BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 06. OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 07. GLOBAL INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 08. RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 09. HSOPITAL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 10. OTHERS INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 11. INFLUENZA TREATMENT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 12. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2026 ($MILLION)
TABLE 13. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 14. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 15. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 16. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 17. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 18. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 19. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026($MILLION)
TABLE 20. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($MILLION)
TABLE 21. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2026 ($MILLION)
TABLE 22. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 23. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 24. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 25. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 26. UK INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 27. UK INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 28. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 29. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 30. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 31. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 32. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026($MILLION)
TABLE 33. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($MILLION)
TABLE 34. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2026 ($MILLION)
TABLE 35. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 36. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 37. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 38. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 39. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 40. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 41. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 43. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026($MILLION)
TABLE 44. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($MILLION)
TABLE 45. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019-2026 ($MILLION)
TABLE 46. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 47. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 48. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 49. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 50. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 51. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026 ($MILLION)
TABLE 53. REST OF LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($MILLION)
TABLE 54. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019-2026($MILLION)
TABLE 55. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($MILLION)
TABLE 56. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 57. ASTRAZENECA: OPERATING SEGMENTS
TABLE 58. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 59. BIOCRYST: COMPANY SNAPSHOT
TABLE 60. BIOCRYST: OPERATING SEGMENTS
TABLE 61. BIOCRYST: PRODUCT PORTFOLIO
TABLE 62. DAIICHI-SANKYO: COMPANY SNAPSHOT
TABLE 63. DAIICHI-SANKYO: OPERATING SEGMENTS
TABLE 64. DAIICHI-SANKYO: PRODUCT PORTFOLIO
TABLE 65. ROCHE: COMPANY SNAPSHOT
TABLE 66. ROCHE: OPERATING SEGMENTS
TABLE 67. ROCHE: PRODUCT PORTFOLIO
TABLE 68. GSK: COMPANY SNAPSHOT
TABLE 69. GSK: OPERATING SEGMENTS
TABLE 70. GSK: PRODUCT PORTFOLIO
TABLE 71. MYLAN: COMPANY SNAPSHOT
TABLE 72. MYLAN: OPERATING SEGMENTS
TABLE 73. MYLAN: PRODUCT PORTFOLIO
TABLE 74. NATCO: SNAPSHOT
TABLE 75. NATCO PHARMA LIMITED: OPERATING SEGMENTS
TABLE 76. NATCO PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 77. NOVARTIS: COMPANY SNAPSHOT
TABLE 78. NOVARTIS AG.: OPERATING SEGMENTS
TABLE 79. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 80. SANOFI: COMPANY SNAPSHOT
TABLE 81. SANOFI: PRODUCT SEGMENTS
TABLE 82. SANOFI: PRODUCT PORTFOLIO
TABLE 83. TEVA: COMPANY SNAPSHOT
TABLE 84. TEVA: OPERATING SEGMENTS
TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO:

List of Figures

FIGURE 01. GLOBAL INFLUENZA TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, INFLUENZA TREATMENT MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ZANAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. U.S. INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 19. CANADA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 20. MEXICO INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 21. GERMANY INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 22. FRANCE INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 23. UK INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 24. ITALY INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 25. REST OF EUROPE INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 26. JAPAN INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 27. CHINA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 28. INDIA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 29. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 30. BRAZIL INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 31. SOUTH AFRICA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 32. SAUDI ARABIA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 33. REST OF LAMEA INFLUENZA TREATMENT MARKET, 2018-2026 ($MILLION)
FIGURE 34. ASTRAZENECA: NET SALES, 2017-2019 ($MILLION)
FIGURE 35. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36. BIOCRYST: NET SALES, 2016-2018 ($MILLION)
FIGURE 37. DAIICHI-SANKYO: NET SALES, 2016-2018 ($MILLION)
FIGURE 38. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 39. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. ROCHE: NET SALES, 2016-2018 ($MILLION)
FIGURE 41. ROCHE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 42. ROCHE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 43. GSK: NET SALES, 2017-2018 ($MILLION)
FIGURE 44. GSK: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 45. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 46. MYLAN: NET SALES, 2016-2018 ($MILLION)
FIGURE 47. MYLAN: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 48. MYLAN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49. NATCO: NET SALES, 2016-2018 ($MILLION)
FIGURE 50. NOVARTIS: NET SALES, 2016-2018 ($MILLION)
FIGURE 51. NOVARTIS: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 52. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53. SANOFI: NET SALES, 2016-2018 ($MILLION)
FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 55. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 56. TEVA: NET SALES, 2016-2018 ($MILLION)
FIGURE 57. TEVA: REVENUE SHARE BY REGION, 2018 (%)

Companies Mentioned
AstraZeneca Plc, BioCryst Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Mylan N.V, Natco Pharma Limited, Novartis AG, Sanofi, and Teva Pharmaceutical Industries Limited.